Positive Expression Of Survivin Research Articles

Significance of detecting the levels of miR-29a, survivin and interferon gamma release assay in patients with lung cancer and tuberculosis.

When lung cancer is combined with concurrent tuberculosis (TB), it increases the difficulty of diagnosis and treatment, leading to missed and/or misdiagnosed cases. To provide reference markers for the clinical diagnosis of patients with lung cancer complicated by active pulmonary TB (APT). The concentration of survivin in diseased tissue, and miR-29a and IGRAs interferon gamma (IFN-γ) in serum were evaluated in 25 patients with non-small cell lung carcinoma (NSCLC) complicated by APT, 32 patients with NSCLC and 30 patients with APT. The expression of miR-29a in serum of patients with APT was higher than in patients with NSCLC complicated by APT (least significant difference (LSD)-t = 4.724, p < 0.001), and the NSCLC group (LSD-t = 6.619, p < 0.001). Furthermore, patients with NSCLC complicated by APT had higher miR-29a concentration than the NSCLC group. The rate of positive survivin expression in NSCLC (χ2 = 23.418, p < 0.001) and NSCLC combined with APT group (χ2 = 17.160, p < 0.001) was significantly higher than in patients with APT. The concentration of IFN-γ in serum of the NSCLC complicated by APT group (LSD-t = 2.912, p = 0.004) and the APT group (LSD-t = 4.452, p < 0.001) was higher than in the NSCLC group. The level of IFN-γ in serum of the NSCLC complicated by APT group were higher than in the APT group, but there was no statistical difference. The levels of MiR-29a, Survivin and IFN-γ was helpful for differential diagnosis of lung cancer and tuberculosis.

Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors

Purpose: The aim of the present study was to evaluate survivin immunoexpression and the clinicopathologic correlations in serous borderline ovarian tumors (BOT) patients ≤ 40 years old.&#x0D; Materials and Methods: A total of 36 BOT cases were evaluated. After excluding the mucinous type and patients over 40 years of age, 20 serous BOT cases meeting the criteria were included. A similar number of benign ovarian cysts and 20 serous malign ovarian tumors were randomly included as the control group. The patients were then staged based on their surgical findings and 2014 FIGO criteria, and their histological tumor types obtained from pathological specimens were determined using WHO criteria. The survivin levels in the specimens were analyzed using immunohistochemical assays.&#x0D; Results: Positive survivin expression was detected in 10% of benign tumors, 100% of serous BOTs, and 100% of serous malign ovarian tumors. Mean survivin immunoreactivity was statistically similar between groups and it was found to be significantly higher in both groups compared to the control group. Survivin expression was positively correlated with FIGO stage, tumor grade, microinvasion, and micropapillary pattern.&#x0D; Conclusion: Survivin immunoexpression is correlated with the malignancy potential of serous BOTs, and that survivin immune expression may be a histopathological marker that will help in making a decision on fertility-sparing surgery and follow upin young patients.

MicroRNA‑93 knockdown inhibits acute myeloid leukemia cell growth via inactivating thePI3K/AKT pathway by upregulating DAB2.

Acute myeloid leukemia (AML) is associated with a poor prognosis in elderly adults and currently lacks optimal treatment strategies. MicroRNAs (miRNAs or miRs) have increasingly been reported to be associated with AML progression; however, the mechanisms of action of miR-93 in AML with the involvement of disabled 2 (DAB2) are currently unknown. In the present study, miR-93 expression was assessed in patients with AML and in AML cell lines. The association between miR-93 expression and the pathological characteristics of patients with AML was analyzed. AML cells were then transfected to knockdown or overexpress miR-93 in order to elucidate its function in AML progression. The target gene of miR-93 was assessed using a dual-luciferase reporter gene assay. The expression levels of miR-93, DAB2 and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway-related proteins were measured and in vivo experiments were conducted to confirm the results. It was observed that miR-93 was highly expressed in patients with AML and in AML cells. The knockdown of miR-93 in HL-60 cells inhibited AML cell proliferation and resistance to apoptosis, while the overexpression of miR-93 in THP-1 cells led to contrasting results. Moreover, miR-93 targeted DAB2 to inactivate the PI3K/AKT pathway, and the overexpression of DAB2 reversed the effects of miR-93 on THP-1 cell growth. Tumor volume, tumor weight, and the positive expression of Ki67, survivin and p53 were increased in THP-1 cells overexpressing miR-93. On the whole, the present study demonstrates that miR-93 is highly expressed in AML cells, and that the suppression of miR-93 inhibits AML cell growth by targeting DAB2 and inhibiting the PI3K/AKT pathway.

THE RNA EXPRESSION LEVEL OF SURVIVIN, OCT 4 AND CYCLIN D1 GENES IN TRIPLE NEGATIVE AND NON-TRIPLE NEGATIVE BREAST CANCER

Background: the purpose of the present study to investigate the RNA expression level of Oct4, Survivin and Cyclin D1 genes in Triple-negative breast cancer (TNBC) and compared to non-triple negative breast cancer (non-TNBC) group. Also, correlate the results of gene expression with clinicopathological features of patients. Method, RNA expression levels of Oct4, Survivin and Cyclin D1 was tested for 100 breast cancer (BC) patients [formalin fixed paraffin embedded tissue (FFPE)] diagnosed as invasive duct carcinoma in Pathology Department, National Cancer Institute (NCI), Cairo University. The qRT-PCR technique is use and the results correlated to clinico-pathological characteristics of patients and survival rates. Result, in (TNBC) patients, oct4, survivin and cyclin D1 showed positive expression in 30 (60%), 32(64%) and 32 (64%) (p < 0.001, p= 0.001 and p= 0.003;respectively). In non-TNBC patients, the positive expression of oct4, survivin and cyclin D1 gene was 11(22%), 15(30%) and 17(34%) (p < 0.001, p= 0.001 and p= 0.003;respectively). All patients in TNBC have negative ER, PR and HER-2 receptor (p=0.001). There was highly statistically significant difference between oct4 gene expression and all the clinico-pathological features except the family history. A significant difference between cyclin D1gene expression and all the clinico-pathological features except the tumor size, tumor grade and lymphnode status. Statistically difference was found between survivin gene expression and all the clinico-pathological features except the menopause state, tumor stage and tumor grade. Triple negative breast cancer patients showed significantly decreased DFS (p < 0.001, log rank) and OS (p= 0.002, log rank) when compared to those with non-TNBC patients. In TNBC group, patients with positive expression of survivin was significantly associated with decreased OS (p= 0.03, log rank). TNBC tumors with positive oct4 and cyclin D1 had reduced OS compared to those negative to oct4 and cyclin D1 but without significant difference (p= 0.8 and p= 0.09, respectively, log rank). In non-TNBC group, with positive oct4, cyclin D1 and survivin did not significantly differ in terms of DFS and OS when compared to those with negative expression. Conclusion: Oct4 and survivin expression gene are better marker used for diagnosis in TNBC and for molecular targeting therapy of TNBC treatment. Cyclin D1 expression used as a marker for aggressive TNBC. The TNBC tumor possibly respond to treatment that downregulates cyclin D1 amplifica tion. More studied and large sample size is needed.

Expression and its clinicopathological significance of Survivin, MSH2 and MSH6 in colorectal cancer

Objective To analyze the changes of Survivin, MSH6 and MSH2 expression in colorectal cancer and explore their relationship with clinical and pathological parameters. Methods 197 cases of colorectal adenocarcinoma and 20 cases of inflammatory intestinal mucosa were detected by immunohistochemistry with Survivin, MSH6 and MSH2, and the correlation between Survivin, MSH6 and MSH2 expression was analyzed. Results In the control group of 20 cases with inflammatory non-tumor intestinal mucosa, the positive expression rate of MSH2, MSH6, Survivin were 95%, 95%, 10%, respectively. While the positive expression rate of MSH2, MSH6, Survivin were 88.3%, 74.1% and 84.3% in 197 cases of colorectal cancer. Survivin positive expression rate in colorectal cancer group was significantly higher than that in inflammatory control group (P 0.05). MSH2 expression was correlated with tumor size and lymph node metastasis (P 0.05). MSH6 expression was related to gender and lymph node metastasis (P 0.05). Colorectal cancer tissues showed positive correlation between MSH6 and MSH2 (r=0.326, P<0.01), positive correlation between MSH2 and Survivin positive expression (r=0.277, P<0.01), and positive correlation between MSH6 and Survivin positive expression (r=0.435, P<0.01). Conclusions The positive expression rate of Survivin in colorectal cancer is high. MSH2, MSH6 and Survivin in colorectal cancer play an important role in the development and progression of colorectal cancer, and can provide evidence for the detection of these three factors, including metastasis risk, prognosis assessment and clinical treatment. In particular, Survivin gene may provide evidence for gene therapy. Key words: Colorectal neoplasms; MutS homolog 2 protein; MutS homolog 6 protein; Survivin

Correlation between serum CTRP3 and CTRP9 levels and glycolipid metabolism in preeclampsia pregnant women

Objective To analyze the changes of Survivin, MSH6 and MSH2 expression in colorectal cancer and explore their relationship with clinical and pathological parameters. Methods 197 cases of colorectal adenocarcinoma and 20 cases of inflammatory intestinal mucosa were detected by immunohistochemistry with Survivin, MSH6 and MSH2, and the correlation between Survivin, MSH6 and MSH2 expression was analyzed. Results In the control group of 20 cases with inflammatory non-tumor intestinal mucosa, the positive expression rate of MSH2, MSH6, Survivin were 95%, 95%, 10%, respectively. While the positive expression rate of MSH2, MSH6, Survivin were 88.3%, 74.1% and 84.3% in 197 cases of colorectal cancer. Survivin positive expression rate in colorectal cancer group was significantly higher than that in inflammatory control group (P 0.05). MSH2 expression was correlated with tumor size and lymph node metastasis (P 0.05). MSH6 expression was related to gender and lymph node metastasis (P 0.05). Colorectal cancer tissues showed positive correlation between MSH6 and MSH2 (r=0.326, P<0.01), positive correlation between MSH2 and Survivin positive expression (r=0.277, P<0.01), and positive correlation between MSH6 and Survivin positive expression (r=0.435, P<0.01). Conclusions The positive expression rate of Survivin in colorectal cancer is high. MSH2, MSH6 and Survivin in colorectal cancer play an important role in the development and progression of colorectal cancer, and can provide evidence for the detection of these three factors, including metastasis risk, prognosis assessment and clinical treatment. In particular, Survivin gene may provide evidence for gene therapy. Key words: Colorectal neoplasms; MutS homolog 2 protein; MutS homolog 6 protein; Survivin

The Expression and clinical Significance of Survivin in renal cell carcinoma

Objective To investigate the effect and significance of Survivin oncogenesis and progression on renal cell carcinoma, and the relationship between Survivin expression and biology behavior(clinical stages, pathological grades and lymphatic metastases)of renal cell carcinoma, providing evidence for diagnosis, therapy and prognosis of renal cell carcinoma. Methods Immunohistochemical analysis was performed to detect the Survivin protein, then carrying out relative analyses between survivin protein expression and clinical stage, pathological grade and lymphatic metastases of renal cell carcinoma. All statistical analyses were carried out with SPSS 21.0 software. The probability of less than 5% was assumed to be statistically significant (P<0.05). Results ①The positive rate of Survivin protein expression on the renal cell carcinoma was 73.1% (19/26), and the positive expression of Survivin wasn't found in the normal renal tissues(0/16). Survivin expressions in renal cell carcinoma were significantly higher than those in normal renal tissues, there was significant difference(P<0.05). ②In stage I-II, the positive rate of Survivin protein was 45.5%(5/11). In stage III-IV, the positive rate of Survivin protein was 93.3%(14/15). There was significant difference between the two groups (P<0.05). There was significant difference between the two groups (P<0.05). ③In the poorly differentiated group and the differentiation group, the positive rate of Survivin protein expression was 92.3%(12/13). In the well-differentiated group, the positive rate of Survivin protein expression was 53.8%(7/13). There was significant difference between the two groups (P<0.05). There was significant difference between the two groups (P<0.05). ④The positive rate of Survivin protein expression was 93.3% (14/15) in patients with lymph node metastasis and 45.5% (5/11) in those without.There was significant association between expression of Survivin protein and metastasis(P<0.05). ⑤There was no association between the expression of Survivin and ages and sexes of patients. Conclusions ①The expressions of Survivin are significantly higher in renal cell carcinoma than those in normal renal tissue, while no expression of Survivin is detected in the normal kidney tissue.②The expressions of Survivin in renal cell carcinoma are positively related to the clinical stages, pathological grades and lymphatic metastases. The expressions of Survivin in Ⅲ and Ⅳ period group are higher than those in Ⅰ and Ⅱ period group, and the expressions in the poorly differentiated group and the differentiation group are higher than in the well-differentiated group. In addition, the expression in the lymph node metastasis group is also higher than those in the other group.③Survivin is expected to become an important biological indicator to evaluate the metastasis and prognosis of renal cell carcinoma, and may be a novel therapeutic target of renal cell carcinoma. Key words: Kidney Neoplasms; Inhibitor of Apoptosis Proteins

Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study.

The aim of this study was to investigate the predictive value of the biomarkers FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas. Immunohistochemical staining of FHIT, p27, and pERK1/ERK2 of 265 patients with salivary gland carcinomas was conducted, and associations with clinico-histopathological data, overall survival, and disease-specific survival were examined. Expression of FHIT (quick score 98.7 vs. 206.4) and p27 (QS 187.3 vs. 244.8) was significantly lower in carcinomas compared to non-tumor control tissue. Loss of FHIT frequently occurred in ACC (55.2%), SDC (68.2%), and SCC (100%). In the totality of tumors, loss of FHIT expression was found in 46.7% (106/227) and was significantly associated with advanced T stage and UICC stage, high-grade histology, loss of p27, PI3K, and survivin. FHIT positivity went along with significantly better overall and disease-specific survival. Negativity of p27 occurred in 28.7% (70/244) of tumors, particularly in SDC (54.4%) and SCC (50%). In the totality of tumors, p27 was associated with advanced patient age, high-grade histology, PI3K, survivin as well as better overall and disease-specific survival (p< 0.05). Positive pERK1/ERK2 expression correlated with positive survivin expression but did not affect overall survival in the totality of tumors. In mucoepidermoid carcinomas, pERK1/ERK2 expression was associated with low-grade malignancy, positive nuclear survivin, and better disease-specific survival. Loss of FHIT and p27 characterizes aggressive tumor growth and unfavorable prognosis in salivary gland cancer. The results may help to stratify patient-specific therapies according to individual tumor characteristics.

The expression characteristics and clinical significance of candidate molecular markers in vocal cord leukoplakia

Objective: To investigate the expression of marker proteins in vocal cord leukoplakia, and to find markers for the early stage of diagnosis and prognosis of precancerous lesions. Methods: The study included 119 cases, 68 cases of vocal cord leukoplakia (22 cases with epithelial simple hyperplasia, 46 cases with epithelial dysplasia), and 51 cases of vocal cords benign lesions(31 cases of vocal cord polyps, 20 cases of Reinke's edema). The expression of p53, Ki-67, p21, Survivin, p16, p27, PTEN, c-Myc and vascular endothelial growth factor (VEGF) in vocal cords leukoplakia were detected, vocal cord benign lesions (vocal cord polyps and Reinke's edema) acted as controls, comparing the expression differences of different pathological tissue. Data was analyzed by SPSS 22.0 software. Results: The expression of p53, p16, Ki-67, VEGF in vocal cord benign lesions and vocal cords leukoplakia with epithelial simple hyperplasia did not show significant differences. There was a grading increase in the positive expression of p53, Ki-67 in the vocal cord leukoplakia with epithelial dysplasia contrasting to those in vocal cord benign lesions and vocal cords leukoplakia with epithelial simple hyperplasia (p53: χ(2)=13.340, P=0.002, Ki-67: χ(2)=53.386, P=0.000). The expression of p27, PTEN, c-Myc in vocal cord benign lesions and vocal cords leukoplakia with epithelial dysplasia did not show significant differences. There was a grading increase in the positive expression of p21 Survivin in vocal cords leukoplakia with epithelial dysplasia contrasting to those in vocal cord benign lesions (P<0.05). Expression of Survivin in vocal cords leukoplakia with mild-moderate epithelial dysplasia showed a significant increase than those in vocal cord benign lesions (P<0.05). The positive expression grade of p21 showed a rising trend (P=0.073) between the different grades of dysplasia. Conclusion: The positive expression grade of p53, Ki-67, p21 Survivin showed an increase in vocal cords leukoplakia with epithelial dysplasia contrasting to those in vocal cord benign lesions, which might be an implication for evaluating the diagnosis and prognosis of precancerous lesions. Expression of p21 was correlated to the degrees of dysplasia and expression of Survivin showed a significant difference in early stage of epithelial dysplasia contrasting to benign lesions.

Expressions and significance of the second mitochondria-derived activator of caspase protein and Survivin in tissues of high-grade intraepithelial neoplasia and esophageal squamous cell carcinoma

Objective To detect the expressions of the second mitochondria-derived activator of caspase protein(Smac) and Survivin in tissues of high-grade intraepithelial neoplasia(HGIN)and esophageal squamous cell carcinoma (ESCC), and explore the influence of Smac and Survivin on occurrence and development of ESCC. Methods The retrospective case-control study was conducted. The clinicopathological data of 45 healthy controls with suspected esophagitis (control group), 41 patients with HGIN (HGIN group) and 57 patients with ESCC (ESCC group) who were admitted to the Qinghai University Affiliated Hospital between January 2012 and December 2014 were collected. Observation indicators included: (1) expressions of Smac and Survivin were detected by immunohistochemistry. (2) Expressions of mRNA of Smac and Survivin in tumor tissues and adjacent tissues were detected by real-time polymerase chain reaction (RT-PCR). (3) Correlation between relative expressions of Smac and Survivin in tumor tissues and adjacent tissues. (4) Relationship between expressions of Smac and Survivin in tumor tissues and clinicopathological factors. Measurement data with normal distribution were represented as ±s. The comparisons among groups was evaluated with the one-way ANOVA. The comparison between tumor tissues and adjacent tissues were analyzed by the paired t test, and comparison of rates was done using the chi-square test and Fisher exact probability. The correlation between expressions of Smac and Survivin was done using the Pearson correlation analysis. Results (1) Expressions of Smac and Survivin were detected by immunohistochemistry. The positive expression rate of Smac of esophageal tissues in the control group, HGIN group and ESCC group were respectively 82.2%(37/45), 43.9%(18/41) and 40.4%(23/57), with a statistically significant difference among the 3 groups (χ2=20.408, P 0.05). The positive expression rate of Smac of adjacent tissues in the ESCC group was 84.2%(48/57), with a statistically significant difference between tumor tissues and adjacent tissues (χ2=20.530, P 0.05). The positive expression rate of Survivin of adjacent tissues in the ESCC group was 15.8%(9/57), with a statistically significant difference between tumor tissues and adjacent tissues (χ2=32.386, P 0.05) and in adjacent tissues (r=-0.197, P>0.05). There was a correlation in the relative expression of Smac between tumor tissues and adjacent tissues (r=0.527, P 0.05). (4) The relationship between the expressions of Smac and Survivin in tumor tissues and clinicopathologic factors: the positive expression of Smac in tumor tissues was 51.6% in men, 9.1% in women, 64.7% in tumor diameter<3 cm, 28.0% in tumor diameter≥3 cm, 60.0% in stage Ⅰ-Ⅱ of TNM stage and 22.7% in stage Ⅲ-Ⅳ of TNM stage, respectively, showing statistically significant differences in the positive expression of Smac in tumor tissues of patients with different gender, tumor diameter and TNM stage (χ2=6.093, 5.567, 6.041, P<0.05). The positive expression of Survivin in tumor tissues was 54.5% in high- and moderate-differentiated tumors, 100.0% in low-differentiated tumors, 75.0% in stageⅠ-Ⅱ and 100.0% in stage Ⅲ-Ⅳ, respectively, showing statistically significant differences in the positive expression of Survivin in tumor tissues of patients with different tumor differentiation and TNM stage (P<0.05). Conclusions The expression of Smac in the progression of esophageal epithelial cells towards to high-grade intraepithelial neoplastia and proliferatoin is inhibited, while expression of Survivin is activated. Smac and Survivin participate in the occurrence of ESCC and maybe play an role in determining the biological features of carcinoma tissues. Key words: Esophageal Neoplasms; Second mitochondria-derived activator of caspase protein; Survivin protein; High-grade esophageal intraepithelial neoplasia

Thymectomy in non thymomatous myasthenia gravis: Impact of pathology on outcome and role of survivin in pathogenesis

BackgroundMyasthenia gravis is an autoimmune disorder characterized by production of acetylcholine receptor antibodies. These antibodies are mainly produced by thymic B-lymphocytes. Our aim was to detect the correlation between thymic pathology and outcome of myasthenia gravis. Moreover, we tried to detect the involvement of survivin as an apoptosis inhibitor in pathogenesis of myasthenia. MethodsThis study was a prospective study conducted on 36 non thymomatous myasthenic patients subjected to thymectomy. Patients were followed for 6 months after operation. Moreover, 36 control normal thymic specimens were obtained from patients operated for open heart surgery. Resected thymic tissue was sent for histopathological examination and immunohistochemical staining by survivin to examine its role in pathogenesis of myasthenia. ResultsPatients were divided into group A with hyperplastic thymus and group B with atrophic thymus. Nine patients had no improvement after surgery and the remaining had variable degrees of clinical improvement. Pathology of thymus did not affect clinical outcome with significant improvement in both groups.Decreased duration of symptoms before surgery and female sex are statistically associated with more improvement of patients' symptoms. Positive expression of survivin was detected in germinal centers of all hyperplastic and atrophic thymuses. All the control thymuses were negative for survivin expression. ConclusionThymectomy for myasthenia gravis is an effective and beneficial procedure even in patients with atrophic thymus. Survivin is expressed in all myasthenic thymuses confirming its role in pathogenesis of myasthenia gravis.

Clinicopathological and prognostic significance of survivin expression in renal cancer patients: a meta-analysis

BackgroundSurvivin has been reported to play a role in the diagnosis and prognosis of renal cell carcinoma (RCC); however, published data on this subject are conflicting.AimTo conduct a meta-analysis to...

Expression of Survivin and vascular endothelial cell growth factor in transitional cell carcinoma of bladder and its clinical significance

Objective To investigate the expression and clinical significance of Survivin and vascular endothelial cell growth factor (VEGF) in transitional cell carcinoma of bladder (BTCC). Methods The immunohistochemical PV-6000 method was used to study the expression level of Survivin and VEGF protein in 146 cases of BTCC and 23 cases of normal bladder tissues. Results The positive expression rate of Survivin and VEGF protein in BTCC was 69.9% (102/146) and 74.7% (109/146) respectively, which was significantly higher than that of bladder normal tissues (P<0.05). The positive expression of Survivin and VEGF had a positive correlation and both were closely related to the histological grade and clinical stages of BTCC (P<0.05). Conclusion Survivin and VEGF may play an important role in the carcinogenesis and progression of BTCC. Key words: Survivin; Vascular endothelial cell growth factor; Transitional cell carcinoma of bladder; Immunohistochemistry

Applied value of apoptosis inhibitory protein survivin in FVAD chemotherapy efficacy for refractory multiple myeloma

Objective To investigate the applied value of apoptosis inhibitory protein Survivin in FVAD (fludarabine, vincristine, epirubicin and dexamethasone) chemotherapy afficay for refractory multiple myeloma. Methods Eighty-three cases of multiple myeloma from hematology inpatient department were selected, including 40 cases of initial multiple myeloma (initial treatment group), who were given VAD scheme (vincristine, epirubicin, dexamethasone) chemotherapy, and 43 cases of refractory multiple myeloma (refractory group), who were given FVAD chemotherapy. Bone marrow was collected from marrow aspiration, and Survivin protein expression was detected by immunohistochemistry. Survival was analyzed using Kaplan-Meier. The difference in Survivin positive expression rate between groups was analyzed, and the relationship between Survivin expressoon and FVAD chemotherapy short- and long-term efficacy was also analyzed. Results The positive Survivin expression rate in refractory group (72.09%) was significantly higher than in initial treatment group (42.50%) with significant differences between two groups (P<0.05). Complete remission rate (4.20%) and the effective rate (22.92%) in positive Survivin group were significantly lower than those (14.20% and 57.14%) in Survivin negative group with differences being significant between two groups (P<0.05). Overall survival and progression free survival in Survivin positive group were significantly lower than those in Survivin negative group (P<0.05). Conclusion Survivin protein positive expression increased significantly in refractory multiple myeloma tissue, indicating the short- and long-term curative effectineness of FVAD chemotherapy is worse. Key words: Apoptosis inhibitory protein; Survivin; Refractory multiple myeloma chemotherapy; Chemotherapy

Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.

BackgroundSurviving expression might serve as a prognostic biomarker predicting the clinical outcome of non-small cell lung cancer (NSCLC). The study was conducted to explore the potential correlation of survivin protein expression with NSCLC and its clinicopathologic characteristics.MethodsPubMed, Medline, Cochrane Library, CNKI and Wanfang database were searched through January 2016 with a set of inclusion and exclusion criteria. Data was extracted from these articles and all statistical analysis was conducted by using Stata 12.0.ResultsA total of 28 literatures (14 studies in Chinese and 14 studies in English) were enrolled in this meta-analysis, including 3206 NSCLC patients and 816 normal controls. The result of meta-analysis demonstrated a significant difference of survivin positive expression between NSCLC patients and normal controls (RR = 7.16, 95 % CI = 4.63-11.07, P < 0.001). To investigate the relationship of survivin expression and clinicopathologic characteristics, we performed a meta-analysis in NSCLC patients. Our results indicates survivin expression was associated with histological differentiation, tumor-node-metastasis (TNM) stage and lymph node metastasis (LNM) (RR = 0.80, 95 % CI = 0.73-0.87, P < 0.001; RR = 0.75, 95 % CI = 0.67-0.84, P < 0.001; RR = 1.14, 95 % CI = 1.01-1.29, P = 0.035, respectively), but not pathological type and tumor size. (RR = 1.00, 95 % CI = 0.93-1.07, P = 0.983; RR = 0.95, 95 % CI = 0.86-1.05, P = 0.336, respectively).ConclusionHigher expression of survivin in NSCLC patients was found when compared to normal controls. Survivin expression was associated with the clinicopathologic characteristics of NSCLC and may serves as an important biomarker for NSCLC progression.

Increased survivin expression and its association with clinical parameters of congenital choledochal cysts.

The aim of the current study was to investigate survivin expression in congenital choledochal cysts (CCCs), and its associations with clinical parameters of CCCs. In total, 121 children with CCCs were included in this study as the case group, and their cysts were staged according to the Todani classification system. Additionally, 49 normal gallbladder specimens from healthy children were included as the control group. Survivin detection was conducted using immunohistochemical staining. Associations between positive survivin expression and clinical parameters of CCCs were then analyzed. Positive survivin expression was observed in the cytoplasm, and was seen as granular with yellow or dark brown staining. In the case group, positive survivin expression was detected in most tissues. Specifically, compared to that of normal tissues, the cystic-shaped and fusiform-shaped CCC tissues had significantly higher positive survivin expression rates (all P < 0.05). Importantly, positive survivin expression was also shown to be significantly associated with gender and histological type (both P < 0.05). In conclusion, increased survivin expression was observed in CCC tissues, and was correlated with certain clinical parameters of CCCs, suggesting a possible prognostic value of survivin for CCC progression.

Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy

Platinum-based chemotherapy is the first-line treatment for non-small cell lung cancer (NSCLC), but the chemotherapy often results in the development of chemoresistance. The present study aimed to explore the prognostic implications of survivin and lung resistance protein (LRP) in advanced NSCLC treated with platinum-based chemotherapy. Tumor samples were collected from 61 hospitalized patients with stage IIIB-IV NSCLC that underwent platinum-based chemotherapy. All patient samples were collected in the Oncology Department of the Third Affiliated Hospital of Guangxi Medical University between January 2006 and January 2011. Cytoplasmic survivin and LRP expression were evaluated using immunohistochemistry. The expression of LRP and survivin reached 77% (47/61) and 76% (45/61), respectively. Positive expression of survivin was associated with a lower median progression-free survival (PFS) time (4 vs. 9 months; P=0.038) and a lower median overall survival (OS) time compared with the absence of survivin expression (9 vs. 16 months; P=0.039). Patients with LRP and survivin expression (n=41) demonstrated a median PFS time of 4 months. However, patients with either LRP or survivin expression (n=10) demonstrated a median PFS time of 8 months, which is similar to the median PFS time of the 10 patients with no expression of LRP and survivin (9 months; P=0.022). Either the expression of survivin or the combined expression of LRP and survivin is associated with a poor prognosis in advanced NSCLC treated with platinum-based chemotherapy.

Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma

Up to date, survivin, a well-known inhibitor of apoptosis, has attracted considerable attention as a potential biomarker and therapeutic target in diffuse large B-cell lymphoma (DLBCL). Nevertheless, there still remains no consensus on heterogeneous results. Herein, a meta-analysis was performed to clarify a convincing significance of survivin status on prognosis and clinicopathology of DLBCL patients.Eligible studies were identified by searching Medline, Embase, Scopus, CNKI, and Wanfang databases (last updated on November 30, 2014). Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Heterogeneity and sensitivity were also analyzed. Moreover, Begg, Egger test, and funnel plots were applied to evaluate the publication bias.We finally included 17 eligible studies with the total number of 1352 patients in the meta-analysis. The pooled results showed that positive survivin expression in DLBCL was associated with inferior overall survival (OS) (HR: 1.880, 95% CI: 1.550-2.270) in patients. Moreover, a significant association was revealed between survivin expression and advanced clinical stage (III + IV) (OR: 0.611, 95% CI: 0.452-0.827), higher International Prognosis Index (IPI) score (Score 3-5) (OR: 0.559; 95% CI: 0.410-0.761), elevated serum lactic dehydrogenase (LDH) (OR: 0.607, 95% CI: 0.444-0.831), presence of bone marrow involvement (OR: 2.127, 95% CI: 1.154-3.921) together with reduced complete remission (CR) rate (OR: 0.478, 95% CI: 0.345-0.662).The results suggest that survivin could be a useful prognostic biomarker, and a promising target for DLBCL therapeutic intervention. Considering limited HR data adjusted for standard prognostic variables could be retrieved, future high-quality studies will be needed in evaluating the independent prognostic value of survivin expression in DLBCL.

Prognostic significance of intracellular survivin in myeloid blast cells as an inhibitor of apoptosis in Egyptian adult acute myeloid leukemia patients

Context Abnormalities in the control of apoptosis play an important role in tumorigenesis. Survivin is one of eight members of the inhibitor of apoptosis protein family that regulates and integrates cell division and suppresses apoptosis. Aim The aim of this study was to assess intracellular expression of survivin on malignant myeloid blast cells and its correlation with clinical outcome, overall survival (OS), and other prognostic factors among adult Egyptian patients with acute myeloid leukemia (AML). Settings and design A total of 120 patients with de-novo AML were treated and followed up in Ain Shams University Hospitals Hematology Units and compared with 60 age-matched and sex-matched normal healthy controls. Patients and methods All patients received induction chemotherapy under a 3 + 7 regime, whereas AML-M3 patients received an all-transretinoic acid-based regime. Detection of intracellular survivin antigen in myeloid blast cells was done by flow cytometry on bone marrow samples at diagnosis and after chemotherapy. Results Survivin expression was higher in AML patients at day 0 compared with healthy controls (P = 0.001). The highest survivin level was seen in AML French American British subtypes M5 and M4. A significant positive correlation was found between patients' age, CD15, CD14, and CD11c expression, whereas negative correlation was found between survivin level and the control group, which included 60 age-matched and sex-matched normal healthy volunteers under complete remission, and event-free survival. Patients with a positive survivin expression have shorter OS compared with patients with a negative survivin expression (log-rank = 3.940, P = 0.047). Conclusion Higher survivin levels at diagnosis predict poor response to chemotherapy and shorter OS (P = 0.016).

Prognostic Significance of Intracellular Survivin in Myeloid Blast Cells As an Inhibitor of Apoptosis in Egyptian Adult Acute Myeloid Leukemia (AML) Patients

Background: The balance between cell death and cell viability is important in tissue homeostasis. Abnormalities in the control of apoptosis play an important role in tumorigenesis ( Altieri Cancer 2013). Survivin is one of eight members of the inhibitor of apoptosis protein family (IAP) that, regulates, integrates cell division and suppresses apoptosis . Over expression of several IAPs has been detected in various hematological malignancies, including acute leukemias, myelodysplastic syndrome , chronic myeloid leukemia , and many types of lymphoid malignancies, such as chronic lymphocytic leukemia and diffuse large B-cell lymphoma. Many publications revealed significant correlation between a high level of IAPs, especially of XIAP and survivin, and tumor progression contributing to leukemogenesis due to deregulated apoptosis. The expression of survivin may be a general feature of cancer and alone or with other antiapoptosis genes such as Bcl-2 , survivin may extend the viability of transformed cells and regulate their susceptibility / resistance to apoptosis-based therapy. For this reason survivin may provide an ideal therapeutic target for its selective expression in neoplasia. Survivin shuttles between the nucleus and the cytoplasm , it effectively inhibits apoptosis, by binding to second mitochondrial activator of caspase .Expressed during embryonic development and by many cancer cell types,but not in the differentiated normal tissue ,survivin is implicated in control of cell survival and regulation of mitosis in cancer( Coumar et al Cancer 2013).Objectives: To assess expression of survivin in Egyptian AML patients, and its correlation to outcome, impact on progression, and survival.Methods: 120 adult Egyptianpatients with AML (52 females and 68 males) were recruited and followed up for 2 years, ( mean age:42.1±13.1years) , 16 patients had AML-M0, 32 AML- M1,32 AML- M2, 12 AML- M3, 16 AML -M4 and 12 AML-M5 ( FAB classification ). A control group of 60 age and sex matched normal healthy volunteers was included.All enrolled patients were treated according to our unit ongoing induction and consolidation regimens(NCCN guidelines). Patients were followed up for two year and outcome was designated as either favorable or unfavorable.Detection of intracellular Survivin antigen in myeloid blast cells was done by flow cytometry on bone marrow samples at D0, D28 and then every 6 month (Kim et al Ann Lab Med 2013).Results: Survivin expression was higher in AML patients at D0 and D28 compared to healthy controls (P=0.001),highest survivin level were seen in AML M5 ( FAB subtypes) followed by AML M4 ,then by AML M1, AML M0, AML M3 and AML M2 subtype. A statistically significant positive correlation was found between age of patient at diagnosis and Survivin expression, also between survivin level at D0 and at D28 among responders patients (P=0.001), also between D0-survivin level of AML patients with favorable response compared to patients with unfavorable response (P=0.005), survivin expression positively correlated with CD15, CD14 and CD11c expression. No statistically significant correlations were found between survivin expression and sex, or with results of cytogenetic studies ,nor with AML FAB subtypes. There was statistically significant negative correlation between survivin level and with Complete remission (CR) ,overall survival (OS) Figure -1. EFS, and PFS. CRand post induction response to chemotherapy occured in patients with negative survivin expression more than in patients with positive survivin expression (P=0.005),and after 2 year follow up patients with positive survivin expression relapsed more (P=0.015).Conclusions: Survivin is important factors involved in control of apoptosis in malignant cells. Survivin expression was found to be higher in elderly AML patients compared to younger patients group, A statistically significant negative correlation was detected between survivin level at D0 and CR,OS,EFS, and PFS. Being preferentially and highly expressed in cancer cells, with little expression in normal tissues,makes it an attractive therapeutic target to inhibit cancer growth by inhibiting extrinsic and intrinsic apoptotic pathways and confers resistance to apoptosis by directly suppressing caspase activity. DisclosuresNo relevant conflicts of interest to declare.